BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol 2021;151:41-53. [PMID: 32253714 DOI: 10.1007/s11060-020-03448-1] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 24.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang T, Zhang H, Han Y, Zheng Q, Liu H, Han M, Li Z. Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine-Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles. Adv Sci (Weinh) 2023;10:e2204961. [PMID: 36698265 DOI: 10.1002/advs.202204961] [Reference Citation Analysis]
2 Deng MY, Debus J, König L. [Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma]. Strahlenther Onkol 2023;199:327-9. [PMID: 36662238 DOI: 10.1007/s00066-023-02049-x] [Reference Citation Analysis]
3 He Y, Zhang X, Zhang S, Zhang Y, Xie B, Huang M, Zhang J, Shen L, Long W, Liu Q. Prognostic RNA-editing signature predicts immune functions and therapy responses in gliomas. Front Genet 2023;14:1120354. [PMID: 36845382 DOI: 10.3389/fgene.2023.1120354] [Reference Citation Analysis]
4 Cumba Garcia LM, Bouchal SM, Bauman MMJ, Parney IF. Advancements and Technical Considerations for Extracellular Vesicle Isolation and Biomarker Identification in Glioblastoma. Neurosurgery 2023. [PMID: 36749103 DOI: 10.1227/neu.0000000000002393] [Reference Citation Analysis]
5 Lugani S, Halabi EA, Oh J, Kohler RH, Peterson HM, Breakefield XO, Chiocca EAA, Miller MA, Garris CS, Weissleder R. Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti-Tumor Immunity in Murine Glioblastoma. Adv Mater 2023;35:e2208782. [PMID: 36427266 DOI: 10.1002/adma.202208782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pineda E, Domenech M, Hernández A, Comas S, Balaña C. Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. Onco Targets Ther 2023;16:71-86. [PMID: 36721854 DOI: 10.2147/OTT.S366371] [Reference Citation Analysis]
7 Li Y, Wang W, Hou X, Huang W, Zhang P, He Y, Wang B, Duan Q, Mao F, Guo D. Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth. Cell Death Dis 2023;14:28. [PMID: 36639372 DOI: 10.1038/s41419-023-05555-z] [Reference Citation Analysis]
8 Mantica M, Drappatz J. Immunotherapy associated central nervous system complications in primary brain tumors. Front Oncol 2023;13:1124198. [PMID: 36874119 DOI: 10.3389/fonc.2023.1124198] [Reference Citation Analysis]
9 Huang B, Zhang J, Zong W, Chen S, Zong Z, Zeng X, Zhang H. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. Front Immunol 2023;14:994698. [PMID: 36923402 DOI: 10.3389/fimmu.2023.994698] [Reference Citation Analysis]
10 Di Giacomo AM, Mair MJ, Ceccarelli M, Anichini A, Ibrahim R, Weller M, Lahn M, Eggermont AMM, Fox B, Maio M. Immunotherapy for brain metastases and primary brain tumors. Eur J Cancer 2023;179:113-20. [PMID: 36521332 DOI: 10.1016/j.ejca.2022.11.012] [Reference Citation Analysis]
11 Barsheshet Y, Voloshin T, Brant B, Cohen G, Koren L, Blatt R, Cahal S, Haj Khalil T, Zemer Tov E, Paz R, Klein-Goldberg A, Tempel-Brami C, Jacobovitch S, Volodin A, Kan T, Koltun B, David C, Haber A, Giladi M, Weinberg U, Palti Y. Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model. Int J Mol Sci 2022;23. [PMID: 36430552 DOI: 10.3390/ijms232214073] [Reference Citation Analysis]
12 Sanchez Gil J, Rabkin SD. An armed oncolytic virus for GBM Destruction. Nat Cancer 2022;3:1274-6. [PMID: 36396753 DOI: 10.1038/s43018-022-00457-z] [Reference Citation Analysis]
13 Fathi M, Razavi SM, Sojoodi M, Ahmadi A, Ebrahimi F, Namdar A, Hojjat-Farsangi M, Gholamin S, Jadidi-Niaragh F. Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. Expert Opin Ther Targets 2022;26:949-61. [PMID: 36527817 DOI: 10.1080/14728222.2022.2160703] [Reference Citation Analysis]
14 Hosseinalizadeh H, Habibi Roudkenar M, Mohammadi Roushandeh A, Kuwahara Y, Tomita K, Sato T. Natural killer cell immunotherapy in glioblastoma. Discov Oncol 2022;13:113. [PMID: 36305981 DOI: 10.1007/s12672-022-00567-1] [Reference Citation Analysis]
15 He Y, Zhang S, Zhang X, Zhang Y, Xie B, Zhang J, Long W, Liu Q. A prognostic cuproptosis gene signature predicts immune function and chemotherapy response in gliomas.. [DOI: 10.21203/rs.3.rs-2155356/v1] [Reference Citation Analysis]
16 Barekat F, Jafary H, Ghobeh M. The effect of administration of A2a receptor antagonist on the activity of A2a R/CD37 pathway and induction of apoptosis in glioblastoma tumor cells in BALB/c mice.. [DOI: 10.21203/rs.3.rs-2120555/v1] [Reference Citation Analysis]
17 Chen D, Liu Z, Wang J, Yang C, Pan C, Tang Y, Zhang P, Liu N, Li G, Li Y, Wu Z, Xia F, Zhang C, Nie H, Tang Z. Integrative genomic analysis facilitates precision strategies for glioblastoma treatment. iScience 2022;25:105276. [PMID: 36300002 DOI: 10.1016/j.isci.2022.105276] [Reference Citation Analysis]
18 Melhem JM, Detsky J, Lim-Fat MJ, Perry JR. Updates in IDH-Wildtype Glioblastoma. Neurotherapeutics 2022;19:1705-23. [PMID: 35641844 DOI: 10.1007/s13311-022-01251-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ghosh M, Lenkiewicz AM, Kaminska B. The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma. Biomedicines 2022;10:2292. [DOI: 10.3390/biomedicines10092292] [Reference Citation Analysis]
20 Huang L, He H, Wang K, Ma X, Chen X, Chen W, Wang X, Jiang X, Feng M. EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma. Biomed Pharmacother 2022;155:113659. [PMID: 36095959 DOI: 10.1016/j.biopha.2022.113659] [Reference Citation Analysis]
21 Li G, Rodrigues A, Kim L, Garcia C, Jain S, Zhang M, Hayden-gephart M. 5-Aminolevulinic Acid Imaging of Malignant Glioma. Surgical Oncology Clinics of North America 2022. [DOI: 10.1016/j.soc.2022.06.002] [Reference Citation Analysis]
22 Koch MS, Zdioruk M, Nowicki MO, Griffith AM, Aguilar-cordova E, Aguilar LK, Guzik BW, Barone F, Tak PP, Schregel K, Hoetker MS, Lederer JA, Chiocca EA, Tabatabai G, Lawler SE. Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma. Molecular Therapy - Oncolytics 2022;26:275-288. [DOI: 10.1016/j.omto.2022.07.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Sun Z, Zhao Y, Wei Y, Ding X, Tan C, Wang C. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma. Front Immunol 2022;13:939523. [DOI: 10.3389/fimmu.2022.939523] [Reference Citation Analysis]
24 Shi J, Yang N, Han M, Qiu C. Emerging roles of ferroptosis in glioma. Front Oncol 2022;12:993316. [DOI: 10.3389/fonc.2022.993316] [Reference Citation Analysis]
25 Lee J, Nicosia M, Silver DJ, Li C, Bayik D, Watson DC, Lauko A, Johnson S, Mcgraw M, Grabowski MM, Kish DD, Desai A, Goodman W, Cameron SJ, Okada H, Valujskikh A, Fairchild RL, Ahluwalia MS, Lathia JD. Sex-specific T cell exhaustion drives differential immune responses in glioblastoma.. [DOI: 10.1101/2022.08.17.503211] [Reference Citation Analysis]
26 Wang G, Wang W. Advanced Cell Therapies for Glioblastoma. Front Immunol 2022;13:904133. [DOI: 10.3389/fimmu.2022.904133] [Reference Citation Analysis]
27 Yang G, Fang Y, Zhou M, Li W, Dong D, Chen J, Da Y, Wang K, Li X, Zhang X, Ma T, Shen G. Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases. Front Oncol 2022;12:948933. [DOI: 10.3389/fonc.2022.948933] [Reference Citation Analysis]
28 Sowińska M, Szeliga M, Morawiak M, Zabłocka B, Urbanczyk-Lipkowska Z. Design, Synthesis and Activity of New N1-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma. Biomolecules 2022;12:1116. [PMID: 36009010 DOI: 10.3390/biom12081116] [Reference Citation Analysis]
29 Li L, Zhou J, Dong X, Liao Q, Zhou D, Zhou Y. Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures. Int Immunopharmacol 2022;109:108929. [PMID: 35700581 DOI: 10.1016/j.intimp.2022.108929] [Reference Citation Analysis]
30 Wu C, Qin C, Long W, Wang X, Xiao K, Liu Q. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. J Big Data 2022;9:92. [PMID: 35855914 DOI: 10.1186/s40537-022-00643-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Matsui JK, Perlow HK, Ritter AR, Upadhyay R, Raval RR, Thomas EM, Beyer SJ, Pillainayagam C, Goranovich J, Ong S, Giglio P, Palmer JD. Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. Biomedicines 2022;10:1763. [DOI: 10.3390/biomedicines10071763] [Reference Citation Analysis]
32 Poot E, Maguregui A, Brunton VG, Sieger D, Hulme AN. Targeting Glioblastoma through Nano- and Micro-particle-Mediated Immune Modulation. Bioorganic & Medicinal Chemistry 2022. [DOI: 10.1016/j.bmc.2022.116913] [Reference Citation Analysis]
33 Rodríguez-camacho A, Flores-vázquez JG, Moscardini-martelli J, Torres-ríos JA, Olmos-guzmán A, Ortiz-arce CS, Cid-sánchez DR, Pérez SR, Macías-gonzález MDS, Hernández-sánchez LC, Heredia-gutiérrez JC, Contreras-palafox GA, Suárez-campos JDJE, Celis-lópez MÁ, Gutiérrez-aceves GA, Moreno-jiménez S. Glioblastoma Treatment: State-of-the-Art and Future Perspectives. IJMS 2022;23:7207. [DOI: 10.3390/ijms23137207] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Sener U, Ruff MW, Campian JL. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives. IJMS 2022;23:7046. [DOI: 10.3390/ijms23137046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
35 Lin YJ, Wu CY, Wu JY, Lim M. The Role of Myeloid Cells in GBM Immunosuppression. Front Immunol 2022;13:887781. [PMID: 35711434 DOI: 10.3389/fimmu.2022.887781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Br J Cancer. [DOI: 10.1038/s41416-022-01864-w] [Reference Citation Analysis]
37 Lerner EC, Edwards RM, Wilkinson DS, Fecci PE. Laser ablation: Heating up the anti-tumor response in the intracranial compartment. Adv Drug Deliv Rev 2022;185:114311. [PMID: 35489652 DOI: 10.1016/j.addr.2022.114311] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
38 Chen X, Zhang Y, Zhao Q, Xiaoqun Chen LB, Zhou Z. Management of dermatologic adverse events associated with tumour treating fields in patients with glioblastoma multiforme: A 27-case series. Asia-Pacific Journal of Oncology Nursing 2022. [DOI: 10.1016/j.apjon.2022.100095] [Reference Citation Analysis]
39 Maszczyk M, Banach K, Karkoszka M, Rzepka Z, Rok J, Beberok A, Wrześniok D. Chemosensitization of U-87 MG Glioblastoma Cells by Neobavaisoflavone towards Doxorubicin and Etoposide. Int J Mol Sci 2022;23:5621. [PMID: 35628432 DOI: 10.3390/ijms23105621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res 2022;41:142. [PMID: 35428347 DOI: 10.1186/s13046-022-02349-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
41 Zhu Y, Song Z, Wang Z, Chen G, Jiang F. Protective Prognostic Biomarkers Negatively Correlated with Macrophage M2 Infiltration in Low-Grade Glioma. Journal of Oncology 2022;2022:1-22. [DOI: 10.1155/2022/3623591] [Reference Citation Analysis]
42 Dongpo S, Zhengyao Z, Xiaozhuo L, Qing W, Mingming F, Fengqun M, Mei L, Qian H, Tong C. Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis. World Neurosurg 2022;160:e61-79. [PMID: 34973444 DOI: 10.1016/j.wneu.2021.12.091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Katt WP, Aplin C, Cerione RA. Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives. Onco Targets Ther 2022;15:277-90. [PMID: 35340676 DOI: 10.2147/OTT.S329262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Tang X, Peng H, Xu P, Zhang L, Fu R, Tu H, Guo X, Huang K, Lu J, Chen H, Dong Z, Dai L, Luo J, Chen Q. Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy. Mol Ther Oncolytics 2022;24:707-18. [PMID: 35317516 DOI: 10.1016/j.omto.2022.01.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Lospinoso Severini L, Bufalieri F, Infante P, Di Marcotullio L. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors? Front Cell Dev Biol 2022;10:854352. [PMID: 35242765 DOI: 10.3389/fcell.2022.854352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Diamantopoulos LN, Appleman LJ. HLA-A*03 and response to immune checkpoint blockade in patients with cancer. The Lancet Oncology 2022;23:e99. [DOI: 10.1016/s1470-2045(22)00086-9] [Reference Citation Analysis]
47 Picca A, Guyon D, Santonocito OS, Baldini C, Idbaih A, Carpentier A, Naccarato AG, Caccese M, Lombardi G, Di Stefano AL. Innovating Strategies and Tailored Approaches in Neuro-Oncology. Cancers (Basel) 2022;14:1124. [PMID: 35267432 DOI: 10.3390/cancers14051124] [Reference Citation Analysis]
48 Ye X, Schreck KC, Ozer BH, Grossman SA. High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes. Expert Rev Anticancer Ther 2022. [PMID: 35130447 DOI: 10.1080/14737140.2022.2038138] [Reference Citation Analysis]
49 Bryant JP, Lu VM, Govindarajan V, Perez-Roman RJ, Levi AD. Immunotherapeutic treatments for spinal and peripheral nerve tumors: a primer. Neurosurg Focus 2022;52:E8. [PMID: 35104797 DOI: 10.3171/2021.11.FOCUS21590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02251-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
51 Chang J, Guo C, Li J, Liang Z, Wang Y, Yu A, Liu R, Guo Y, Chen J, Huang S. EN1 Regulates Cell Growth and Proliferation in Human Glioma Cells via Hedgehog Signaling. Int J Mol Sci 2022;23:1123. [PMID: 35163043 DOI: 10.3390/ijms23031123] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
52 Persico M, Abbruzzese C, Matteoni S, Matarrese P, Campana AM, Villani V, Pace A, Paggi MG. Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma. Cells 2022;11:263. [DOI: 10.3390/cells11020263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Malliou A, Kyritsis AP, Alexiou GA. Immunotherapeutic Strategies for Glioma Treatment. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_71] [Reference Citation Analysis]
54 Wang X, Wang X, Li J. Overcoming T-cell exhaustion in glioblastoma: A narrative review. Glioma 2022;5:56. [DOI: 10.4103/glioma.glioma_16_22] [Reference Citation Analysis]
55 Doello K, Mesas C, Quiñonero F, Rama AR, Vélez C, Perazzoli G, Ortiz R. Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines. Neurotox Res 2022;40:1645-52. [PMID: 36447028 DOI: 10.1007/s12640-022-00606-3] [Reference Citation Analysis]
56 Chen J, Mao S, He Z, Yang L, Zhang J, Lin JM, Lin ZX. Proteomic Distributions in CD34+ Microvascular Niche Patterns of Glioblastoma. J Histochem Cytochem 2022;70:99-110. [PMID: 34751042 DOI: 10.1369/00221554211058098] [Reference Citation Analysis]
57 Naulaerts S, Borras DM, Martinez AA, Messiaen J, Van Herck Y, Gelens L, Venken T, Vanmeerbeek I, More S, Sprooten J, Bechter O, Bergers G, Liston A, De Vleeschouwer S, Van Den Eynde BJ, Lambrechts D, Borst J, Bosisio F, Tejpar S, De Smet F, Garg AD. Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy.. [DOI: 10.1101/2021.11.22.468617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Khajanchi S, Nieto JJ. Spatiotemporal dynamics of a glioma immune interaction model. Sci Rep 2021;11:22385. [PMID: 34789751 DOI: 10.1038/s41598-021-00985-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
59 Prapa M, Chiavelli C, Golinelli G, Grisendi G, Bestagno M, Di Tinco R, Dall'Ora M, Neri G, Candini O, Spano C, Petrachi T, Bertoni L, Carnevale G, Pugliese G, Depenni R, Feletti A, Iaccarino C, Pavesi G, Dominici M. GD2 CAR T cells against human glioblastoma. NPJ Precis Oncol 2021;5:93. [PMID: 34707200 DOI: 10.1038/s41698-021-00233-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
60 Panitz V, Končarević S, Sadik A, Friedel D, Bausbacher T, Trump S, Farztdinov V, Schulz S, Sievers P, Schmidt S, Jürgenson I, Jung S, Kuhn K, Pflüger I, Sharma S, Wick A, Pfänder P, Selzer S, Vollmuth P, Sahm F, von Deimling A, Heiland I, Hopf C, Schulz-Knappe P, Pike I, Platten M, Wick W, Opitz CA. Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics 2021;11:9217-33. [PMID: 34646367 DOI: 10.7150/thno.60679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Arnesen VS, Gras Navarro A, Chekenya M. Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. Cancers (Basel) 2021;13:4986. [PMID: 34638471 DOI: 10.3390/cancers13194986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Shah S, Chu Y, Cegielski V, Chu XP. Acid-Sensing Ion Channel 1 Contributes to Weak Acid-Induced Migration of Human Malignant Glioma Cells. Front Physiol 2021;12:734418. [PMID: 34557113 DOI: 10.3389/fphys.2021.734418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 Burster T, Traut R, Yermekkyzy Z, Mayer K, Westhoff MA, Bischof J, Knippschild U. Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. Front Cell Dev Biol 2021;9:695325. [PMID: 34485282 DOI: 10.3389/fcell.2021.695325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
64 Lin YJ, Wei KC, Chen PY, Lim M, Hwang TL. Roles of Neutrophils in Glioma and Brain Metastases. Front Immunol 2021;12:701383. [PMID: 34484197 DOI: 10.3389/fimmu.2021.701383] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
65 Chen A, Jiang Y, Li Z, Wu L, Santiago U, Zou H, Cai C, Sharma V, Guan Y, McCarl LH, Ma J, Wu YL, Michel J, Shi Y, Konnikova L, Amankulor NM, Zinn PO, Kohanbash G, Agnihotri S, Lu S, Lu X, Sun D, Gittes GK, Wang Q, Xiao X, Yimlamai D, Pollack IF, Camacho CJ, Hu B. Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. J Clin Invest 2021;131:147552. [PMID: 34228644 DOI: 10.1172/JCI147552] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
66 Mathios D, Srivastava S, Kim T, Bettegowda C, Lim M. Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors. Neuromolecular Med 2021. [PMID: 34297308 DOI: 10.1007/s12017-021-08677-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Bufalieri F, Basili I, Di Marcotullio L, Infante P. Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis. Front Mol Neurosci 2021;14:710171. [PMID: 34305530 DOI: 10.3389/fnmol.2021.710171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Nwagwu CD, Adamson DC. Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma? Expert Opin Pharmacother 2021;:1-12. [PMID: 34219576 DOI: 10.1080/14656566.2021.1950139] [Reference Citation Analysis]
69 Urbantat RM, Vajkoczy P, Brandenburg S. Advances in Chemokine Signaling Pathways as Therapeutic Targets in Glioblastoma. Cancers (Basel) 2021;13:2983. [PMID: 34203660 DOI: 10.3390/cancers13122983] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
70 Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. Front Neurosci 2021;15:662064. [PMID: 34113233 DOI: 10.3389/fnins.2021.662064] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
71 Knudsen AM, Rudkjøbing SJ, Sørensen MD, Dahlrot RH, Kristensen BW. Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas. J Neuropathol Exp Neurol 2021;80:541-51. [PMID: 33990845 DOI: 10.1093/jnen/nlab041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
72 Frederico SC, Hancock JC, Brettschneider EES, Ratnam NM, Gilbert MR, Terabe M. Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma. Front Oncol 2021;11:672508. [PMID: 34041034 DOI: 10.3389/fonc.2021.672508] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
73 Jiang H, Yu K, Cui Y, Ren X, Li M, Yang C, Zhao X, Zhu Q, Lin S. Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study. Front Immunol 2021;12:632547. [PMID: 34025640 DOI: 10.3389/fimmu.2021.632547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Cho YA, Kim D, Lee B, Shim JH, Suh YL. Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas. J Neurooncol 2021;153:43-53. [PMID: 33864561 DOI: 10.1007/s11060-021-03710-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Burster T, Gärtner F, Bulach C, Zhanapiya A, Gihring A, Knippschild U. Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells. Pharmaceuticals (Basel) 2021;14:236. [PMID: 33800301 DOI: 10.3390/ph14030236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
76 Martínez Bedoya D, Dutoit V, Migliorini D. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. Front Immunol 2021;12:640082. [PMID: 33746981 DOI: 10.3389/fimmu.2021.640082] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
77 Majc B, Novak M, Kopitar-Jerala N, Jewett A, Breznik B. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development. Cells 2021;10:265. [PMID: 33572835 DOI: 10.3390/cells10020265] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 17.0] [Reference Citation Analysis]
78 Jin K, Mao C, Chen L, Wang L, Liu Y, Yuan J. Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma. Cancers (Basel) 2021;13:E229. [PMID: 33435205 DOI: 10.3390/cancers13020229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
79 Bay JO, Andre T, Bouleuc C, Gandemer V, Magne N, Orbach D, Pellier I, Penel N, Rodrigues M, Thariat J, Thiery-Villemin A, Wisley M, L'Allemain G, Robert J; Comité de rédaction du Bulletin du cancer. [What should we remember from 2020?]. Bull Cancer 2021;108:55-66. [PMID: 33419531 DOI: 10.1016/j.bulcan.2020.12.002] [Reference Citation Analysis]
80 Otazu GK, Dayyani M, Badie B. Role of RAGE and Its Ligands on Inflammatory Responses to Brain Tumors. Front Cell Neurosci 2021;15:770472. [PMID: 34975408 DOI: 10.3389/fncel.2021.770472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Butt OH, Zhou AY, Huang J, Leidig WA, Silberstein AE, Chheda MG, Johanns TM, Ansstas G, Liu J, Talcott G, Nakiwala R, Shimony JS, Kim AH, Leuthardt EC, Tran DD, Campian JL. A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Neurooncol Adv 2021;3:vdab164. [PMID: 34988450 DOI: 10.1093/noajnl/vdab164] [Reference Citation Analysis]
82 Wood MD, Neff T, Nickerson JP, Sayama C, Raslan AM, Ambady P, Corless CL, Nazemi KJ. Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation. Neuropathol Appl Neurobiol 2021;47:460-3. [PMID: 33296093 DOI: 10.1111/nan.12679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Li L, Zhu X, Qian Y, Yuan X, Ding Y, Hu D, He X, Wu Y. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future. Front Immunol 2020;11:594271. [PMID: 33224149 DOI: 10.3389/fimmu.2020.594271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
84 Huang S, Song Z, Zhang T, He X, Huang K, Zhang Q, Shen J, Pan J. Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas. Front Immunol 2020;11:585034. [PMID: 33193404 DOI: 10.3389/fimmu.2020.585034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
85 Wang Z, Guo X, Gao L, Wang Y, Ma W, Xing B. Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients. Aging (Albany NY) 2020;12:18297-321. [PMID: 32957084 DOI: 10.18632/aging.103695] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]